[Event Report] The First Advisory Board Meeting of the Project for Considering the Future of Precision Medicine with Industry, Government, Academia, and Civil Society (December 14, 2021)
date : 12/21/2021
Tags: NCDs, Precision Cancer Medicine
Health and Global Policy Institute (HGPI)/NCD Alliance Japan held the first advisory board meeting of the “Project for Considering the Future of Precision Medicine with Industry, Government, Academia, and Civil Society.” To prevent the potential spread of Coronavirus Disease 2019 (COVID-19), the meeting was held entirely online and was closed to the public.
Since the Cancer Control Act was enacted in 2007, Japan has implemented comprehensive cancer control measures based on five-year plans called Basic Plans to Promote Cancer Control Programs. Under the current program, the third-term Basic Plan to Promote Cancer Control Programs (2018-2022), steps are being taken to “promote precision medicine using cancer genome analysis technologies,” a field which has seen remarkable progress in recent years. These initiatives are to serve as a pillar for field-centric measures aiming to “improve cancer treatment.” Widespread availability of diagnoses and treatments based on cancer genome information is likely to enable the provision of preferential treatments that are optimized for the individual, reducing physical and mental burdens on patients.
However, there are issues that must be addressed in every aspect of precision medicine. For example, tests used to examine abnormalities across multiple genes related to cancer development called cancer gene panels are generally only available to patients who have completed standard treatments currently granted coverage in the insurance system. This means some patients see their conditions worsen between testing and treatment, while others are unable to find the pharmaceutical that best suits them. As a result, only 10% to 20% of patients are able to persevere until the optimal treatment is found. In the future, various issues that must be resolved include determining the timing and number of these tests, achieving equity in the cancer genome therapy provision system through which this testing is provided, and balancing testing with public finances.
In response, HGPI/NCD Alliance Japan launched this project to stimulate collaborative discussions with domestic and international stakeholders and to formulate effective policy recommendations. At the first advisory board meeting, we gathered opinion leaders and related parties in this field representing industry, Government, academia, and civil society to hold a discussion that focused mainly on the four points listed below.
1. Improving access to precision medicine (namely, testing and treatment)
2. Striking a sustainable balance with public finance
3. Further promoting research and development
4. Ethical, Legal and Social Issues (ELSIs) and other issues surrounding the above three items.
■ Event overview
Date and time: Tuesday, December 14, 2021; from 13:00 to 15:00
Venue: Online using the Zoom conferencing system
Host: Health and Global Policy Institute (HGPI)
■ First Advisory Board Meeting participants (Titles omitted; in no particular order)
Ataru Igarashi (Associate Professor, Unit of Public health and Preventive Medicine, Yokohama City University School of Medicine)
Mitsuho Imai (Project Assistant Professor, Shinanomachi Cancer Center, School of Medicine, Keio University)
Hiroji Iwata (Vice Director and Chief, Department of Breast Oncology, Aichi Cancer Center Hospital)
Atsushi Otsu (Director, National Cancer Center Hospital East)
Shinji Kosugi (Professor, Medical Ethics and Medical Genetics, Department of Social Medicine, Graduate School of Medicine and Faculty of Medicine, Kyoto University)
Naomi Sakurai (President, Cancer Solutions Co., Ltd)
Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital)
Yusuke Tsugawa (Associate Professor, David Geffen School of Medicine (Internal Medicine), University of California, Los Angeles (UCLA); Associate Professor, Health Policy and Management; Faculty Associate, UCLA Center For Health Policy)
Kazuo Hasegawa (Representative, NPO Lung Cancer Patient Association One Step)
Yoshiyuki Majima (Chairman, NPO PanCAN Japan)
Tetsuya Mitsutomi (Professor/Senior Staff, Division of Thoracic Surgery, School of Medicine, Kindai University)
Takayuki Yoshino (Director, Department of Gastrointestinal Oncology, National Cancer Center Hospital East)
Reiko Akizuki (Director, Oncology Department, Medical Affairs Division, Janssen Pharmaceutical K.K.)
Kosuke Iijima (Head, Foundation Medicine Business Department, Chugai Pharmaceutical Co., Ltd.)
Sotaro Enatsu (General Manager, Oncology Business Unit, Research and Development and Medical Affairs, Eli Lilly Japan K.K.)
日本語
Top Research & Recommendations Posts
- [Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Dementia Prevention Initiatives for Achieving a Dementia-Friendly and Inclusive Society (March 26, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Announcement] HGPI Joins Global Climate and Health Alliance (March 23, 2024)
- [Policy Recommendations] Three Necessary Perspectives for Formulating the Basic Plan for the Promotion of Policies on Dementia: Creating a Society That is Inclusive for All People at All Times (April 1, 2024)
Featured Posts
-
2024-04-12
[Announcement] HGPI Joins Global Climate and Health Alliance (March 23, 2024)
-
2024-04-16
[Activity Report] HGPI Child Health Project Selected to Implement FY2024 Nippon Foundation Grant Program, “Establishing a Skill Development Program and Collaborative Network for Improving Mental Health for Students with Intellectual Disabilities” (April 15, 2024)
-
2024-04-18
[Event Report] NCDs-related Cross-project Meeting: The 2nd Meeting on Non-Communicable Disease in Hokkaido and Tohoku (March 15, 2024)
-
2024-04-23
[Registration Open] The 125th HGPI Seminar: Progress and Prospects for Domestic Measures on Health Problems Caused by Alcohol (May 24 , 2024)